Issue 14, 2025

Exploring the anticancer potential of new pyrazolopyrimidine analogues as multi-target directed EGFR/STAT3 downregulatory candidates with apoptotic potential

Abstract

Cancer causes about 8 million deaths each year. The EGFR plays a pivotal role in prompting cells to grow and survive, making it a major target for cancer treatment. Besides, STAT3 is essential for the development, growth, and maintenance of tumors. Moreover, multitarget-directed ligands can potentially offer better treatment results and improve the health of patients. Hence, novel pyrazolopyrimidine analogues (6a–l) were designed to effectively inhibit both EGFR and STAT3 for cancer therapy by preserving the principal pharmacophores of EGFR and STAT3 inhibitors. Growth inhibition (GI)% of the pyrazolopyrimidines (6a–l) was recorded towards eleven cancer and one normal cell lines. Obviously, compound 6k revealed the highest mean GI% (65.61%) in comparison to doxorubicin (76.41%). Besides, compound 6k exhibited notably the lowest IC50 (48.11 μM) in MDA-MB-468 cells in comparison to doxorubicin (11.39 μM), whereas compound 6h showed the lowest IC50 (27.84 μM) in MDA-MB-231 cells surpassing doxorubicin (30.74 μM). In addition, compounds 6e and 6h displayed the most prominent inhibitory potential among the assessed compounds by remarkably downregulating EGFR and STAT3 protein expression, respectively. Furthermore, the apoptotic potential of compound 6k was pursued. The protein expressions of caspases 3, 8, and 9 as apoptotic markers were increased by 1.77, 1.36, and 1.25-fold, respectively. Besides, the protein expressions of CDK-2, 4, and 6 as anti-apoptotic markers were downregulated by 0.36, 0.70, and 0.66-fold, respectively. Furthermore, it was shown that compound 6k halted the G0 and S phases of the cell cycle by increasing the cellular levels to 13.84 and 28.22%, compared to 8.47 and 20.02% of the control cells, respectively. Accordingly, the afforded analogues can be considered lead anticancer ligands acting as dual EGFR/STAT3 inhibitors for further optimization.

Graphical abstract: Exploring the anticancer potential of new pyrazolopyrimidine analogues as multi-target directed EGFR/STAT3 downregulatory candidates with apoptotic potential

Supplementary files

Article information

Article type
Paper
Submitted
27 Jan 2025
Accepted
10 Mar 2025
First published
10 Mar 2025

New J. Chem., 2025,49, 6025-6037

Exploring the anticancer potential of new pyrazolopyrimidine analogues as multi-target directed EGFR/STAT3 downregulatory candidates with apoptotic potential

A. A. Al-Karmalawy, A. A. Elmaaty, A. Y. M. Alabdali, S. Shaaban, A. O. A. Khatib, M. H. Abdellattif, A. A. Alnjaa, M. Sharaky, W. M. Eldehna and A. A. Gaber, New J. Chem., 2025, 49, 6025 DOI: 10.1039/D5NJ00367A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements